T-1301

T-1301 is a novel small molecule multi-targeted tyrosine kinase inhibitor (TKI) developed for the treatment of various cancers. It inhibits multiple tyrosine kinases, disrupting tumor cell signaling pathways and suppressing proliferation. T-1301 has demonstrated potent inhibition against both wild-type and mutant forms of several kinases, including those resistant to existing therapies such as imatinib (Glivec/Gleevec), sunitinib (Sutent), and regorafenib (Stivarga). Preclinical studies have shown efficacy in acute myeloid leukemia (AML), gastrointestinal stromal tumors (GIST) with drug-resistant mutations, as well as a range of solid tumors including colorectal cancer, gastric cancer, lung cancer, nasopharyngeal cancer, oral cancer, ovarian cancer, triple-negative breast cancer, and multidrug resistance protein 1-driven chemorefractory tumors. The drug is formulated for oral administration with acceptable bioavailability in animals and humans. As of 2022–2025 it is undergoing Phase I clinical trials to evaluate safety/tolerability and preliminary anti-tumor activity[1][2][3][5].